In order to elucidate whether TCR-bypass-stimulated γδ T cells can be a therapeutic tool for cancers, we systematically analyzed the effects of IL-2, IL-12, IL-18 and that of TCR stimulation on γδ T cells and directly compared their impact on proliferation, activation, cytokine production, and anti-tumoral activity in vitro. This evidence concerns the gene IL18 and cancer.